Innate Pharma SA (FR:IPH) has released an update.
Innate Pharma SA, a French biotechnology company focused on developing immunotherapies for cancer, has released its half-year financial report as of June 30, 2024. The company emphasizes its innovative approach through therapeutic antibodies and a proprietary platform, highlighting its lead programs like lacutamab for T cell lymphomas. Amidst forward-looking statements, Innate Pharma underlines the inherent risks in research and development while maintaining its commitment to advancing its clinical trials and product candidates.
For further insights into FR:IPH stock, check out TipRanks’ Stock Analysis page.
